Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
220.02B
Market cap220.02B
Price-Earnings ratio
26.96
Price-Earnings ratio26.96
Dividend yield
2.53%
Dividend yield2.53%
Average volume
2.61M
Average volume2.61M
High today
$387.55
High today$387.55
Low today
$379.34
Low today$379.34
Open price
$382.00
Open price$382.00
Volume
1.93M
Volume1.93M
52 Week high
$398.00
52 Week high$398.00
52 Week low
$269.77
52 Week low$269.77

Stock Snapshot

The current Amgen(AMGN) stock price is $385.20, with a market capitalization of 220.02B. The stock trades at a price-to-earnings (P/E) ratio of 26.96 and offers a dividend yield of 2.53%.

On 2026-08-01, Amgen(AMGN) stock traded between a low of $379.34 and a high of $387.55. Shares are currently priced at $385.20, which is +1.5% above the low and -0.6% below the high.

The Amgen(AMGN)'s current trading volume is 1.93M, compared to an average daily volume of 2.61M.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $398.00 at its peak.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $398.00 at its peak.

AMGN News

Reuters 20h
Amgen discloses data breach involving patient health information - Reuters

...

Amgen discloses data breach involving patient health information - Reuters
Seeking Alpha 21h
Amgen hit by cybersecurity incident, sensitive data stolen

Amgen (AMGN) said on Friday that it was hit by a cybersecurity incident in July where sensitive data stored in the cloud, including proprietary information and...

Amgen hit by cybersecurity incident, sensitive data stolen
TipRanks 21h
Amgen says cybersecurity incident not likely to have material impact

According to a regulatory filing, in July 2026, Amgen (AMGN) identified unauthorized activity involving data stored in cloud environments hosted by third-party...

Analyst ratings

49%

of 35 ratings
Buy
40%
Hold
48.6%
Sell
11.4%

More AMGN News

Simply Wall St 2d
How Investors May Respond To Amgen Repatha Expansion and 2026 Dividend Declaration

Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to share...

How Investors May Respond To Amgen Repatha Expansion and 2026 Dividend Declaration
Nasdaq 3d
Amgen Stock Moves -1.44%: What You Should Know

Amgen (AMGN) closed at $387.42 in the latest trading session, marking a -1.44% move from the prior day. The stock outperformed the S&P 500, which registered a d...

Amgen Stock Moves -1.44%: What You Should Know
TipRanks 3d
Amgen Halts Key Bemarituzumab Gastric Cancer Trial, Narrowing Near-Term Upside for AMGN

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Simply Wall St 3d
Amgen Stock Could Be A Bargain On Cash Flow But Fairly Priced On Earnings

Amgen stock has delivered an 88.5% total return over the past five years, and the latest Discounted Cash Flow (DCF) estimate currently points to the shares trad...

Amgen Stock Could Be A Bargain On Cash Flow But Fairly Priced On Earnings
Nasdaq 3d
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Key Points Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task. Its competitors are...

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
TipRanks 5d
Amgen Halts Key Phase 3 Rocatinlimab Study, Resetting Expectations in Dermatology

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Simply Wall St 6d
Amgen Beat Revenue Forecasts, Is The Stock Overvalued?

Amgen (AMGN) is back in focus after quarterly revenue of $8.62b surpassed analyst forecasts, with management pointing to double digit growth across 16 brands an...

Amgen Beat Revenue Forecasts, Is The Stock Overvalued?

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.